Cannabichromene / Casp3 Cancer Research Results

CBC, Cannabichromene: Click to Expand ⟱
Features:
Cannabichromene (CBC) is a phytocannabinoid found in the Cannabis plant. It has anti-inflammatory, antitumor and anticonvulsant properties, and may affect THC psychoactivity.

Cannabichromene (CBC) is a non-psychotropic phytocannabinoid produced by Cannabis sativa through decarboxylation of cannabichromenic acid (CBCA). It is formally classified as a plant-derived small-molecule cannabinoid and, in oncology, is best considered an exploratory adjunctive natural product rather than an established anticancer drug. Standard abbreviation: CBC. Current evidence supports a receptor-mixed pharmacology centered on CB2-preferring signaling, TRPA1 activity, and modulation of endocannabinoid tone, but the human evidence base remains sparse.

Primary mechanisms (ranked):

  1. CB2 receptor agonism with predominantly anti-inflammatory and immunomodulatory signaling
  2. TRPA1 activation and subsequent desensitization, relevant to inflammatory and nociceptive modulation
  3. Endocannabinoid tone modulation through inhibition of endocannabinoid cellular uptake and weak MAGL inhibition
  4. Suppression of inflammatory nitric oxide output in activated macrophages
  5. Context-dependent antiproliferative and pro-apoptotic effects in cannabinoid-containing extract systems, with CBC often acting as one component rather than a fully validated stand-alone anticancer effector
  6. Clinical translation constraint from variable oral exposure, first-pass metabolism, formulation dependence, and limited human efficacy data

Bioavailability / PK relevance: CBC is lipophilic and formulation-sensitive. Human oral PK data exist, but mainly from mixed cannabinoid oil products rather than purified CBC. Oral exposure is variable, first-pass metabolism is relevant, and current PK reviews identify low/variable bioavailability and limited clinical PK characterization as major translational constraints.

In-vitro vs systemic exposure relevance: This is an important limitation. Mechanistic and antiproliferative findings are mainly preclinical, and many in-vitro cannabinoid concentrations used in oncology-oriented studies are likely above readily achievable systemic exposure with currently described oral human CBC dosing. CBC is therefore more plausible at present as a pharmacology signal or adjunctive lead than as a validated concentration-achievable stand-alone anticancer agent.

Clinical evidence status: Preclinical and early human PK only. No established CBC-specific randomized oncology efficacy trials were identified. Regulatory/clinical use is not established for purified CBC as an approved anticancer drug.

Mechanistic interpretation

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CB2 signaling ↓ inflammatory support signals (context-dependent) ↓ inflammatory activation R-G Immunomodulatory anti-inflammatory bias Best-supported direct receptor mechanism. CBC behaves as a selective CB2 agonist with little meaningful CB1 activity in the cited receptor studies. Anticancer leverage is indirect and context-dependent rather than firmly cytotoxic.
2 TRPA1 activation desensitization ↔ direct tumor kill uncertain ↓ nociceptive and inflammatory signaling P-R Sensory-inflammatory modulation TRPA1 appears mechanistically relevant for CBC pharmacology. In oncology this is more plausible for inflammation/pain biology than for a robust stand-alone tumoricidal mechanism.
3 Endocannabinoid tone AEA uptake MAGL ↔ mixed ↔ mixed R-G Indirect ECS amplification CBC has been reported to inhibit endocannabinoid cellular reuptake and weakly inhibit MAGL, which could alter local endocannabinoid tone. Net cancer relevance is model-dependent and presently secondary.
4 Macrophage nitric oxide inflammatory axis ↓ pro-tumor inflammatory milieu (possible) ↓ NO output in activated macrophages R-G Anti-inflammatory effector suppression Strong preclinical evidence shows CBC reduces nitrite / nitric oxide output in activated macrophages and improves murine colitis. This supports anti-inflammatory action but not a CBC-specific clinical anticancer effect.
5 Apoptosis and migration inhibition ↓ viability; ↓ migration/invasion (extract-dependent) ↔ unknown G Preclinical antiproliferative signal Anticancer findings exist in bladder and other experimental systems, but CBC is often part of active extract fractions or cannabinoid combinations. Attribution to purified CBC alone remains lower-confidence than for its anti-inflammatory pharmacology.
6 Estrogen receptor antagonism ↓ ER signaling (weak, high concentration only) ↔ uncertain R Possible endocrine interaction Recent breast-cancer-related in vitro work suggests CBC can show ER antagonism at 10 μM, but this is not yet a core validated mechanism and may be influenced by concurrent cell-viability effects.
7 ROS NRF2 ↔ not established as core ↔ not established as core Not a primary defining axis ROS/NRF2 are not well established as central CBC mechanisms from current higher-confidence sources, so they should not be foregrounded for this product at present.
8 Clinical Translation Constraint Exposure limitations Exposure limitations G PK and evidence bottleneck Human PK data show measurable oral exposure, but formulation dependence, first-pass metabolism, sparse monotherapy data, and lack of CBC-specific oncology trials materially limit translation. Many in-vitro oncology concentrations may exceed realistic systemic exposure.

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
6608- Ech,  CBC,    The pro-apoptosis effects of Echinacea purpurea and Cannabis sativa extracts in human lung cancer cells through caspase-dependent pathway
- in-vitro, Lung, A549
tumCV↓, Apoptosis↑, TumCCA↑, ROS↑, Casp3↑, TumCD↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Casp3↑, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:53  Target#:42  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page